Phibro Animal Health Corp - Class A risk profile
40 Elevated one input has moved against it
Measured 21 October 2026 from PAHC's filed statements. Recomputed nightly.
40 (Elevated), driven by Cash conversion at 64, over 6 weighted categories on the MANUFACTURER profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 63 | Stretched | Volatile | One-year price volatility — 54.1% |
| Operating pressure | 22 | Normal | Easing | Operating-margin drift — +5.5 percentage points |
| Cash conversion | 64 | Stretched | Worsening | Capital spending against operating cash — 0.86x |
| Leverage and coverage | 39 | Normal | Easing | Net debt to EBITDA — 3.12x |
| Competitive position | 31 | Normal | Stable | Operating-margin gap against peers — +9.1 percentage points |
| Concentration | 54 | Elevated | Stable | Geographic concentration — 4,050 HHI |
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Healthcare companies with a risk reading
Lilly(Eli) & Company 33Johnson & Johnson 39Abbvie Inc 57Unitedhealth Group Inc 43Roche Holding AG 35Merck & Co Inc 35Novartis AG 29Novartis AG 31Astrazeneca plc 33Thermo Fisher Scientific Inc 44AMGEN Inc 47Gilead Sciences Inc 51
Financials, valuation and price history for Phibro Animal Health Corp - Class A